Dr. Albert Friesen reports

MEDICURE ANNOUNCES AGM RESULTS AND APPOINTMENT OF NEW DIRECTOR

Medicure Inc. has released the voting results from its annual general meeting of shareholders held today, including the appointment of Kerrie Hayes to the board of directors of the company. A total of 5,237,796 common shares (representing 50.19 per cent of the votes attached to all outstanding common shares of the company as at the record date) were voted in person or by proxy at the meeting. All resolutions presented to shareholders were approved. More specifically, shareholders voted in favour of:

• Setting the number of directors at five, with the following five nominees elected as directors: Dr. Albert Friesen, Dr. Arnold Naimark, James Kinley, Brent Fawkes and Ms. Hayes; and
• Reappointing Ernst & Young LLP as auditor of the company.

Dr. Friesen, chief executive officer of the company, commented: "On behalf of Medicure, I would like to thank shareholders for their participation and continued support. We are pleased to welcome Kerrie Hayes to the board as an independent director and look forward to her contributions, particularly in the areas of applied research, business development and intellectual property management."

Ms. Hayes is currently the director, research contracts, at the University of Manitoba. In this role, she provides institutional oversight for complex research agreements and international partnership contracting. Previously, Ms. Hayes was director of business development at Medicure and intellectual property manager at a life science incubator. She holds an MSc in biosciences from the University of Winnipeg.

The company also announces that Peter Quick has stepped down as a director of Medicure as of the time of the meeting. "Personally and on behalf of the board, I want to acknowledge and express my sincere thanks for Peter's many contributions to Medicure over the past 20 years and wish him the very best moving forward," stated Dr. Friesen.

About Medicure Inc.

Medicure is a company focused on the development and commercialization of pharmaceuticals and health care products for patients and prescribers in the U.S. market. The present focus of the company is the marketing and distribution of Aggrastat (tirofiban hydrochloride) injection and Zypitamag (pitavastatin) tablets in the United States, where they are sold through the company's U.S. subsidiary, Medicure Pharma Inc. Medicure also operates Marley Drug Inc., a pharmacy subsidiary servicing all 50 states, Washington, D.C., and Puerto Rico. Marley Drug is committed to improving access to medications for all Americans together with exceptional customer service and free home delivery. Medicure also operates Gateway Medical Pharmacy, located in Portland, Ore., in a medical office building near major transportation lines and multiple health care clinics and centres. In addition to regular customers, the pharmacy services multiple long-term-care facilities and provides non-sterile compounding services. Medicure also operates West Olympia Pharmacy, located in Olympia, Wash., in a medical office complex near multiple clinics.

We seek Safe Harbor.